Transformed Sandoz Is Important Part Of Novartis

09 Jan 2019

• By Aidan Fry

A Sandoz generics division that is focusing more on biosimilars and hard-to-make small molecules remains “an important part of Novartis”, the Swiss group’s chief executive officer, Vas Narasimhan, told investors during a J.P. Morgan Healthcare Conference.

Sandoz remains “an important part of Novartis”, even as it exits solid-dose and dermatology generics in the US, the Swiss group’s chief executive officer, Vas Narasimhan, told investors during a J.P. Morgan Healthcare Conference.

Speaking in San Francisco, US, Narasimhan said transforming Sandoz would be “critical for our future”. Pointing out that Novartis had...